PathoFinder is a privately owned molecular diagnostics company founded in 2004. The company focuses on the development and commercialization of comprehensive panels, with special emphasis on infectious diseases. PathoFinder's proprietary 2SmartFinder® technology enables the detection and differentiation of up to 24 viral, bacterial, fungal and parasitic pathogens in a single assay. PathoFinder is based in Maastricht, The Netherlands. The company’s founder and CEO is Guus Simons, PhD. Before founding PathoFinder, Guus Simons worked at KeyGene (Wageningen, The Netherlands) for eleven years, where he held positions as project manager and business manager and for nine years as project leader at the Netherlands Institute for Dairy Research (NIZO). He performed a post-doc period at the University of Ghent, Belgium after he got his PhD in molecular biology at the University of Nijmegen, The Netherlands. Guus Simons has written more than 75 peer reviewed papers and 15 patent applications.
PathoFinder is dedicated to the development, validation and production of high quality, sensitive and robust single reaction multiplex assays, for the detection of pathogens causing an infectious disease. Our products are compatible with many commercially available detection systems to enable a rapid introduction into molecular diagnostics laboratories. PathoFinder will continue to develop new assays for several panel diseases such as Respiratory Tract Infections (RTI’s), Gastroenteritis, Central Nervous System Infections, Sexually Transmitted Diseases (STD’s) and detection of Resistance markers.
PathoFinder has an EN ISO 13485:2016 certified Quality Management System for the design and development, manufacturing and distribution of In-Vitro Diagnostics for infectious diseases. In addition, we are certified as meeting the requirements of Directive 98/79/EC on IVD Medical Devices. Quality Control for Molecular Diagnostics (QCMD, www.qcmd.org
) is an international External Quality Assessment (EQA) provider for molecular diagnosis of infectious agents. QCMD has an extensive EQA portfolio with a wide range of clinically relevant infectious diseases and includes schemes for the assessment of microbial load, genotyping and drug resistance. In the past years PathoFinder has successfully participated in all applicable EQA programs for both the 2SmartFinder® and RealAccurate® products. Details of these tests are available on request.